PCI Pharma Services, a company that provides integrated pharmaceutical development services to the global healthcare market, is investing more than USD20m to expand its biotech technologies, including advanced injectable delivery forms, at multiple locations across the world, to meet demand for biotech packaging, it was reported yesterday.

The company will add expanded Biotech clinical and commercial packaging and release testing capability at its Center of Excellence in Philadelphia, and expanded Cold Chain capacity at numerous global locations to further support its present Biotech infrastructure.

The firm's latest investment will include capacity expansion for cutting edge technologies for the labelling and assembly of state-of-the-art safety syringes, auto-injector and pen devices with integrated high speed cartoning, in-line serialisation, as well as furthering its expansive onsite Cold Chain storage. Its injectable delivery form capabilities include ampoules, vials, cartridges and standard prefilled syringes, as well as advanced safety syringes, autoinjectors and pen devices with services including both simple and complex kitting for clinical and commercial applications.